Skip to main content

Endologix Value Stock - Dividend - Research Selection

Endologix

ISIN: US29266S1069, WKN: 909659

Market price date: 30.11.-0001
Market price: 0,00 USD




Endologix Fundamental data and company key figures of the share

Annual reports in USD
Key figures 16-03-2020
Cash flow
Net operating cash flow -29.570.000
Capital Expenditures -455.000
Free cash flow -30.025.000
Balance sheet
Total Equity 63.856.000
Liabilities & Shareholders equity 307.164.000
Income statement
Net income -64.757.000
Eps (diluted) -3,840
Diluted shares outstanding 16.863.800
Net sales/revenue 143.370.000

Fundamental ratios calculated on: 30-11--0001

Ratios
Key figures 30-11--0001
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI0,00
ROE0,00
Income statement
P/E0,00
Div. Yield0,00%
P/B0,00
P/S0,00


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolELGX
Market Capitalization337.276,00 USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internetwww.endologix.com


Description of the company

Endologix, Inc. (Endologix) is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company´s principal product is a stent graft and delivery system (ELG System), for the treatment of abdominal aortic aneurysms (AAA) through endovascular repair (EVAR). Its ELG System consists of a self-expanding cobalt chromium alloy stent covered by expanded polytetrafluoroethylene (ePTFE) graft material (ELG Device) and an accompanying delivery catheter. Once its ELG Device is fixed in its proper position within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for the AAA to rupture. Its ELG System consists of the Company´s ELG Device and catheter delivery system. It also offers proximal aortic extensions and limb extensions, which attach to the main body of its ELG Device.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.endologix.com